

Attachment 13: BEEA IRB Approval Signature Pages

13.1). BEEA IRB NCI

13.2). BEEA IRB Westat

13.3). BEEA IRB University of Iowa



iRIS Reference Number 320222

Amendment Letter: B
IRB Number: 10CN106
Version Date: 03/30/2012

04/25/2012

TO: Michael Alavanja
NCI - Occupational and Environmental Epidemiology Branch

FROM: Chairperson, Special Studies Institutional Review Board, NCI

SUBJECT: Action on Clinical Research Protocol Amendment

Your amendment to protocol, "Study of Biomarkers of Exposure and Effects in Agriculture," was reviewed by the National Cancer Institute Special Studies Institutional Review Board (NCI-SSIRB) by expedited review.

The SSIRB has taken the following action:

X	Approved as written. Forwarded to the CC OPS for administrative processing.
	Approved with stipulations pending re-review by SSIRB Chair. See review comments.
	Deferred pending response to stipulations and re-review by a subcommittee of the Board. See review comments.
	Tabled pending response to stipulations and re-review by the full SSIRB. See review comments.



An Employee-Owned
Research Corporation

1650 Research Boulevard
Rockville, MD 20850-3195
tel: 301-251-1500
fax: 301-294-2040
www.westat.com

AMENDMENT REVIEW FORM

(TO ADD OR CHANGE PREVIOUSLY APPROVED RESEARCH)

All changes or new activities for previously approved studies require submission, review and approval of an Amendment Request. Please complete and submit this form to irb@westat.com and attach all necessary materials to be reviewed. Once reviewed, you will be contacted. If this change or new activity requires a full Board review, those meetings occur on the second Tuesday of every month. To check the date of meetings, please see the [meeting schedule](#) under IRB in WesInfo. Thank you for your cooperation.

1. Today's Date:	03 / 14 / 2012	
Date of Original Approval:	11 / 28 / 2010	
Project Name:	Biomarker Study	
Westat Project Number:	8970.1.2.2	(8970.01.02.02)
Agency Grant or Contract Number:	HHSN261201100017C	
Project Director:	Marsha Dunn	Ext. 3557
Unit Ops Number/Study Area:	21.72.01	
Area IRB Rep:	Nancy Weinfield	

2. Indicate the type of addition or change being requested to a previously approved study.

(SELECT ALL THAT APPLY.)

- | | |
|---|--|
| <input type="checkbox"/> Name (s) of investigators | <input type="checkbox"/> Review of final instrument such as interview questions or data collection sites for a previously approved study |
| <input type="checkbox"/> Project Number | <input type="checkbox"/> Mode of administration of instruments in your study (e.g., from mail or telephone to web or Internet access) |
| <input type="checkbox"/> Introduction of a new IRB or request for Westat to serve as the IRB | <input type="checkbox"/> Data access rights |
| <input type="checkbox"/> Study design, survey questionnaire or procedure (s) | <input type="checkbox"/> Any other change in protocol that affects treatment of human subjects: |
| <input checked="" type="checkbox"/> Informed consent process, consent form (s), parent permission (s), or assent form (s) | (PLEASE SPECIFY) |
| <input type="checkbox"/> Recruitment materials or strategies | |
| <input type="checkbox"/> Incentives | |
| <input checked="" type="checkbox"/> Survey instruments | |
| <input type="checkbox"/> Number or type of populations studied | |

IRB Office Only

APPROVED – NEXT CONTINUING REVIEW DATE: _____

CONDITIONAL APPROVAL (PLEASE SEE ATTACHED LETTER)

DID NOT QUALIFY FOR EXPEDITED REVIEW

3. Please provide a brief summary of your change or addition to previously approved research.

In North Carolina, Westat will conduct the CATI screener, schedule the phlebotomy appointment in the home, send urine kits to participants, administer informed consent, conduct the CAPI, collect blood, urine, and dust (as applicable), and ship the samples to the designated laboratory.

4. How does each change or addition affect the risks to participants in your study? (PLEASE SELECT ONLY ONE.)

- a. No change
- b. N/A -- no risks
- c. Decreases the risk (SPECIFY):

[Empty box for specifying risk decrease]

- d. Increases the risk (SPECIFY):

[Empty box for specifying risk increase]

- e. Adds a new risk (SPECIFY):

[Empty box for specifying new risk]

SIGNATURE – Sign here or deliver through electronic email from your computer.

The information provided in this request form is complete and correct.

Project Director/Principal Investigator: Marsha Rupp Date: 3/14/2012

Please attach:

- One document that clearly identifies (through track changes, highlights, or italics) the revision in the previously approved submission.
- Another document labeled “corrected version.”

If you have any questions, feel free to contact Sharon Zack, IRB Administrator, at ext. 8828.

IRB Administration Use Only

Expedited review and approval for the modification(s) on this form:

Sharon Zack IRB Chair / Associate Chair / Designee March 26, 2012 Date

IRB Office Only

APPROVED – NEXT CONTINUING REVIEW DATE: 11/2012

CONDITIONAL APPROVAL (PLEASE SEE ATTACHED LETTER)

DID NOT QUALIFY FOR EXPEDITED REVIEW

Protection of Human Subjects
Assurance Identification/IRB Certification/Declaration of Exemption
(Common Rule)

Policy: Research activities involving human subjects may not be conducted or supported by the Departments and Agencies adopting the Common Rule (56FR28003, June 18, 1991) unless the activities are exempt from or approved in accordance with the Common Rule. See section 101(b) of the Common Rule for exemptions. Institutions submitting applications or proposals for support must submit certification of appropriate Institutional Review Board (IRB) review and approval to the Department or Agency in accordance with the Common Rule.

Institutions must have an assurance of compliance that applies to the research to be conducted and should submit certification of IRB review and approval with each application or proposal unless otherwise advised by the Department or Agency.

201002777

1. Request Type <input type="checkbox"/> ORIGINAL <input checked="" type="checkbox"/> CONTINUATION <input type="checkbox"/> EXEMPTION	2. Type of Mechanism <input type="checkbox"/> GRANT <input checked="" type="checkbox"/> CONTRACT <input type="checkbox"/> FELLOWSHIP <input type="checkbox"/> COOPERATIVE AGREEMENT <input type="checkbox"/> OTHER: _____	3. Name of Federal Department or Agency, or organization, and, if known, Application or Proposal Identification No. US Department of Health & Human Services, National Institutes of Health // Westat, Inc. 8970-S01
4. Title of Application or Activity Biomarkers of Exposures and Effects in Agriculture (BEEA) Study		5. Name of Principal Investigator, Program Director, Fellow, or Other Charles Lynch

6. Assurance Status of this Project (*Respond to one of the following*)


- This Assurance, on file with Department of Health and Human Services, covers this activity:
 Assurance Identification No. FWA00003007, the expiration date 11/08/2013 IRB Registration No. IRB00000099
- Exemption Status: Human subjects are involved, but this activity qualifies for exemption under Section 101(b), paragraph .

7. Certification of IRB Review (*Respond to one of the following IF you have an Assurance on file*)

- This activity has been reviewed and approved by the IRB in accordance with the Common Rule and any other governing regulations.
 by: Full IRB Review -- date of IRB meeting: or Expedited Review
 Approval Date: 12/29/11
 Expiration Date: 12/28/12
- This activity contains multiple projects, some of which have not been reviewed. The IRB has granted approval on condition that all projects covered by the Common Rule will be reviewed and approved before they are initiated and that appropriate further certification will be submitted.

8. Comments

Contract Title: The Agricultural Health Study (AHS) Phase IV

9. The official signing below certifies that the information provided above is correct and that, as required, future reviews will be performed until study closure and certification will be provided.	10. Name and Address of Institution The University of Iowa Human Subjects Office Office of the Vice President for Research 340 Medicine Administration Bldg The University of Iowa Iowa City, IA 52242-1101	
11. Phone No. (<i>with area code</i>) 319-335-6564 12. Fax No. (<i>with area code</i>) 319-335-7310 13. Email: James-walker@uiowa.edu	15. Title Associate Vice President for Research - Regulatory Affairs	
14. Name of Official James C Walker, PhD	17. Date 12/29/11	
16. Signature 		

Authorized for local Reproduction

Sponsored by HHS

Public reporting burden for this collection of information is estimated to average less than an hour per response. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: OS Reports Clearance Officer, Room 503 200 Independence Avenue, SW., Washington, DC 20201. Do not return the completed form to this address.



Attachment 13a: Phase IV Buccal Iowa

Agricultural Health Study- Iowa

University of Iowa • 2500 Crosspark Road, Suite W240 • Coralville IA 52241 •
1.800.217.1954

www.aghealth.org

[date]

Executive Committee

Michael C. R. Alavanja, DrPH
Occupational and Environmental
Epidemiology Branch
National Cancer Institute
National Institutes of Health
U.S. Department of Health and
Human Services
Executive Plaza South, RM8000
Rockville, MD 20892

Laura Beane Freeman, PhD
Occupational and Environmental
Epidemiology Branch
National Cancer Institute
National Institutes of Health
U.S. Department of Health and
Human Services
Executive Plaza South, RM8112
Rockville, MD 20892

Jane A. Hoppin, ScD
Epidemiology Branch
National Institute of Environmental
Health Sciences
National Institutes of Health
U.S. Department of Health and
Human Services
P.O. Box 12233
Mail Drop A3-05
Research Triangle Park, NC 27709

Dale P. Sandler, PhD
Epidemiology Branch
National Institute of Environmental
Health Sciences
National Institutes of Health
U.S. Department of Health and
Human Services
P.O. Box 12233
Mail Drop A3-05
Research Triangle Park, NC 27709

Kent Thomas, BSPH
U.S. Environmental Protection Agency
National Exposure Research
Laboratory
109 T.W. Alexander Drive, MD E205
Research Triangle Park, NC 27709

Cynthia J. Hines, MS, CIH
Division of Surveillance, Hazard
Evaluations, and Field Studies
National Institute for Occupational
Safety and Health
4676 Columbia Parkway, R-14
Cincinnati, OH 45226

Coordinating Center

Marsha Dunn, MPH
Westat
1600 Research Blvd.
Rockville, MD 20850

Charles F. Lynch, MD, PhD
University of Iowa
College of Public Health, Dept. of
Epidemiology
105 River Street, Room S447 CPHB
Iowa City, IA 52242

To: *Agricultural Health Study Participant*

From: Charles Lynch, M.D., Ph.D.
Director, Agricultural Health Study-Iowa

Thank you for continuing to participate in the Agricultural Health Study, which is designed to learn about how occupation and environmental factors affect an individual's health. Thanks to your participation, this now is the largest one of its kind in the United States.

The main goal of this study is to look at pesticide exposures and chronic health conditions. Now that we are learning more about possible links between various cancers and pesticide use, we would like you to consider participating in an additional research effort. You are one of about 5,000 members of the Agricultural Health Study who have been selected to be contacted about this study. Because you have already contributed a tremendous amount of information about your pesticide exposure in previous interviews and questionnaires, this new study will have a head-start in understanding the relationship of cancer to these exposures.

We would like you to collect a sample of loose cells from your mouth. You may have done so for us in a previous effort, but this sample will be reserved specifically for later laboratory analysis that will involve genetic testing. Your participation will take only a few minutes and will provide important information for the study.

We will be calling you within a few days to explain the procedure and answer any questions you may have. In the meantime, if you have any questions, please call us at **1-800-217-1954**. We will be glad to assist you.

Thank you once again for your time and support.

Attachment 14: Phase IV Buccal North Carolina

[date]

To: *Agricultural Health Study Participant*

From: Marsha Dunn, MPH
Director, Agricultural Health Study-North Carolina

Thank you for continuing to participate in the Agricultural Health Study, which is designed to learn about how occupation and environmental factors affect an individual's health. Thanks to your participation, this now is the largest one of its kind in the United States.

The main goal of this study is to look at pesticide exposures and chronic health conditions. Now that we are learning more about possible links between various cancers and pesticide use, we would like you to consider participating in an additional research effort. You are one of about 5,000 members of the Agricultural Health Study who have been selected to be contacted about this study. Because you have already contributed a tremendous amount of information about your pesticide exposure in previous interviews and questionnaires, this new study will have a head-start in understanding the relationship of cancer to these exposures.

We would like you to collect a sample of loose cells from your mouth. You may have done so for us in a previous effort, but this sample will be reserved specifically for later laboratory analysis that will involve genetic testing. Your participation will take only a few minutes and will provide important information for the study.

We will be calling you within a few days to explain the procedure and answer any questions you may have. In the meantime, if you have any questions, please call us at **1-800-4AGSTUDY**. We will be glad to assist you.

Thank you once again for your time and support.